To assess the effects of obesity on pulmonary function, 46 healthy subjects exhibiting various degrees of obesity underwent lung function tests. Subjects were divided into three groups according to body mass index (BMI): 13 had minimal obesity (BMI, 25 to 29 kg/m2, group 1); 24 had a BMI in the 30 to 40 range (group 2); and 9 displayed to morbid obesity (BMI > 40, group 3). Respiratory resistance was estimated by the forced random noise oscillation technique and airway resistance was determined by body plethysmography. Lung volumes and expiratory flows were also determined and significant negative correlations with BMI were found. Expiratory flows diminished in proportion to lung volumes, and the ratio of forced expiratory volume in 1 s to forced vital capacity was within normal limits. Although expiratory flows did not suggest bronchial obstruction, both respiratory resistance and airway resistance rose significantly with the level of obesity (p < 0.005 and p < 0.025, respectively), from 3.2 (+/- 0.02) and 3.2 (+/- 0.02) cm H2O.s.L-1, respectively, in group 1, to 5.5 (+/- 0.06) and 5.0 (+/- 0.05), respectively, in group 3. Evaluation of the factors responsible for this increased resistance disclosed a significant linear correlation between airway conductance and functional residual capacity (r = 0.70, p < 10(-4)), but specific airway conductance was found to be independent of the degree of obesity. The difference between respiratory resistance and airway resistance did not widen significantly according to the level of obesity, suggesting that chest wall resistance was not a factor enhancing these resistances. Taken together, these findings suggest that in addition to the elastic load, obese subjects have to overcome increased respiratory resistance resulting from the reduction in lung volumes related to being overweight.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1378/chest.103.5.1470 | DOI Listing |
Infection
January 2025
Department of Pediatric Respiratory Medicine, Children's Hospital, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530003, People's Republic of China.
Background: Mycoplasma pneumoniae is a prevalent pathogen in pediatric community-acquired pneumonia. Currently, limited literature exists on the clinical utilization of pathogen-targeted sequencing technologies.
Methods: Targeted next-generation sequencing (tNGS) technology was employed to analyze bronchoalveolar lavage fluid (BALF) from 1,070 hospitalized pediatric patients with acute lower respiratory tract infections.
Mol Divers
January 2025
Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian, China.
Influenza is a highly contagious respiratory illness that imposes a significant global burden. Antiviral neuraminidase inhibitors (NAIs) such as oseltamivir (OC) have been proven essential, but the emergence of resistant viral strains necessitates the development of novel therapies. This study explored the potential of natural products as alternative NAIs.
View Article and Find Full Text PDFAdv Sci (Weinh)
January 2025
National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, No.2 Yuanmingyuan West Road, Beijing, 100193, China.
Most antibiotics are ineffective against Gram-negative bacteria owing to the existence of the outer membrane (OM) barrier. The rational design of compounds to expand their antibacterial spectra of antibiotics solely targeting Gram-positive pathogens remains challenging. Here, the design of skeletons from natural products to penetrate the OM are deciphered.
View Article and Find Full Text PDFTranspl Infect Dis
January 2025
Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Background: Infections are a common complication among lung transplant recipients (LuTR), particularly in the first year post-transplant, with respiratory tract infections (RTI) being predominant. Syndromic molecular panels have been suggested to reduce morbidity and mortality by providing a diagnosis quickly. However, integrating these panels into clinical practice remains debated.
View Article and Find Full Text PDFFEBS Open Bio
January 2025
Department of Pharmacology-Physiology-Toxicology, Institute of Pharmaceutical and Biological Sciences of Lyon, University Claude Bernard Lyon 1, France.
Non-small cell lung cancer (NSCLC) affects 10-50% of patients with epidermal growth factor receptor (EGFR) mutations. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that radically changes the outcome of patients with tumors bearing EGFR sensitizing or EGFR T790M resistance mutations. However, resistance usually occurs, and new therapeutic combinations need to be explored.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!